News from indivior plc A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Sep 10, 2018, 08:00 ET Indivior Prepays $150 Million of Outstanding Debt

Indivior PLC (LON: INDV) today announced that it has completed the prepayment of $150 million of its outstanding Term loan facilities. As a result,...


Jul 31, 2018, 08:03 ET Indivior Preliminary Injunction on Generic (buprenorphine and naloxone) Sublingual Film Upheld

Indivior PLC (LON: INDV) (Indivior or the Company) today announced that the U.S. Court of Appeals for the Federal Circuit (CAFC) has denied Dr....


Jul 25, 2018, 02:45 ET Indivior Announces H1 2018 Results

Period to June 30th Q2 2018 $m Q2 2017 $m % ∆ Actual FX % ∆ Constant FX H1 2018 $m H1 2017 $m % ∆ Actual FX % ∆ Constant FX Net Revenue 268 288 -7 -8 ...


Jul 13, 2018, 18:22 ET Indivior Is Granted Preliminary Injunction on Generic (buprenorphine and naloxone) Sublingual Film

Indivior PLC (LON: INDV) ("Indivior" or the "Company") today announced that the U.S. District Court for the District of New Jersey has granted a...


Jul 11, 2018, 07:47 ET Indivior Sees FY 2018 Net Revenue and Adjusted Net Income Below Previous Expectations

Indivior PLC (LON: INDV) ("Indivior" or the "Company") today announced that its previous FY 2018 financial guidance (net revenue: $1,130m - $1,170m;...


Jul 10, 2018, 09:00 ET Indivior to Announce and Present Half Year 2018 Results on July 25th

Indivior PLC (LON: INDV) today announced that it will release its half year 2018 results on July 25th at 7:00 a.m. London time (2:00 a.m. U.S. EDT)....


Jun 28, 2018, 06:07 ET Indivior's Temporary Restraining Order is Extended

Indivior PLC (LON: INDV) ("Indivior" or the "Company") today announced that the U.S. District Court for the District of New Jersey heard Indivior's...


Jun 15, 2018, 10:11 ET Indivior Responds to Generic SUBOXONE® Approvals and Dr. Reddy's Launch "At-Risk"

Indivior PLC (LON: INDV) ("Indivior" or the "Company") today announced that it is aware that, on 14 June 2018, the US FDA approved generic versions...


Jun 15, 2018, 08:00 ET Indivior Is Granted Temporary Restraining Order

Indivior PLC (LON: INDV) ("Indivior" or the "Company") today announced that the U.S. District Court for the District of New Jersey has granted...


May 31, 2018, 08:45 ET Indivior Receives Subpoena from California Department of Insurance

Indivior PLC (LON: INDV) announced today that Indivior Inc., its wholly owned subsidiary, received a subpoena from the Office of the Insurance...


May 25, 2018, 09:55 ET Indivior Announces Regulatory Submission to Australia's Therapeutic Goods Administration (TGA) for SUBLOCADE™ (Buprenorphine Extended-Release) Injection for the Treatment of Opioid Dependence

Indivior PLC (LON: INDV) today announced that it has filed a regulatory submission with Australia's Therapeutic Goods Administration (TGA) for...


May 24, 2018, 09:55 ET Indivior's Mark Crossley to Participate in Jefferies 2018 Global Healthcare Conference on June 5th

Indivior PLC (LON: INDV) today announced that Mark Crossley, CFO, will participate in Jefferies 2018 Global Healthcare Conference on Tuesday, June...


May 14, 2018, 08:00 ET Indivior Enters into Settlement with Par Pharmaceutical in Patent Infringement Case

Indivior PLC (LON: INDV) ("Indivior" or the "Company") today announced that its U.S. subsidiary, Indivior Inc., together with Aquestive Therapeutics, ...


Apr 11, 2018, 08:00 ET Indivior to Announce First Quarter 2018 Results on May 2nd and Host Conference Call

Indivior PLC (LON: INDV) today announced that it will release its first quarter 2018 results on May 2nd at 12:00 p.m. London time (7:00 a.m. U.S....


Mar 29, 2018, 08:00 ET Indivior Enters Into an Exclusive Global License Agreement for C4X Discovery's Orexin-1 (OX1) Antagonist Program

Indivior PLC ("Indivior") (LON: INDV) today announced that its subsidiary Indivior UK Limited ("Indivior UK") and C4X Discovery Holdings PLC ("C4X")...


Mar 01, 2018, 08:00 ET SUBLOCADE™ (Buprenorphine Extended-Release) is Now Available as First and Only Monthly Injectable Buprenorphine in the U.S. to Treat Patients with Moderate to Severe Opioid Use Disorder

Indivior PLC (LON: INDV) today announced that SUBLOCADE™ (buprenorphine extended-release) injection, for subcutaneous use (CIII), is now available in ...


Feb 08, 2018, 10:28 ET Indivior Files Complaints Asserting New SUBOXONE® Film Patent Against ANDA-filers

Indivior PLC (LON: INDV) ("Indivior" or the "Company") today announced that its U.S. subsidiary, Indivior Inc., has filed patent lawsuits against Dr. ...


Jan 19, 2018, 08:59 ET Indivior to Announce Full Year 2017 Results on February 15th

Indivior PLC (LON: INDV) today announced that it will release its full year 2017 results on February 15th at 7:00 a.m. London time (2:00 a.m. U.S....


Jan 04, 2018, 08:00 ET Indivior's Shaun Thaxter to Present at the 36th Annual J.P. Morgan Healthcare Conference on January 11th

Indivior PLC (LON: INDV) today announced that Shaun Thaxter, CEO, will present at the 36th Annual J.P. Morgan Healthcare Conference on January 11th,...


Jan 03, 2018, 08:00 ET Indivior and Addex Enter Strategic Collaboration to Accelerate Development of GABA(B) PAMs for Addiction Disorder Treatments

Indivior PLC (LON: INDV) ("Indivior") today announced that Indivior UK Limited has entered into a strategic collaboration with Addex Pharma S.A., a...


Dec 12, 2017, 06:00 ET Indivior Announces NDA Acceptance of RBP-7000 Risperidone Monthly Depot

Indivior PLC (LON: INDV) (the 'Company') today announces that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) ...


Oct 31, 2017, 16:58 ET FDA Advisory Committees Recommend Approval of Indivior's RBP-6000 for the Treatment of Opioid Use Disorder

Indivior PLC (LON: INDV) announced today that the Psychopharmacologic Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee ...


Jul 31, 2017, 08:30 ET Indivior PLC Announces FDA Acceptance with Priority Review Designation of RBP-6000 Buprenorphine Monthly Depot New Drug Application (NDA) for the Treatment of Opioid Use Disorder

Indivior PLC (LON: INDV) today announces that the U.S. Food and Drug Administration (FDA) has accepted with a Priority Review designation the New...


Jun 21, 2017, 12:24 ET Indivior PLC Presents Results from the Phase 3 Pivotal Study of RBP-6000 Buprenorphine Monthly Depot for the Treatment of Opioid Use Disorder

Indivior PLC (LON: INDV) today announced the presentation of results from its pivotal Phase 3 clinical trial (RB-US-13-0001) evaluating the efficacy...


Nov 17, 2016, 09:39 ET Indivior Applauds United States Surgeon General Dr. Vivek Murthy's Report on Substance Misuse and Substance Use Disorders

Indivior PLC (LON: INDV) commends U.S. Surgeon General Dr. Vivek Murthy for the robust report released today titled, "Facing Addiction in America:...